A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy
Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein that plays several roles in cancer biology. EpCAM is an attractive therapeutic target because of its expression in most solid tumors. However, targeting EpCAM has been challenging because it is also highly expressed in normal...
Saved in:
| Main Authors: | Gerhard Frey, Ana Paula G. Cugnetti, Haizhen Liu, Charles Xing, Christina Wheeler, Hwai Wen Chang, William J. Boyle, Jay M. Short |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2024.2322562 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development of a bispecific antibody–drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors
by: Meiying Luo, et al.
Published: (2025-03-01) -
Novel human single-domain antibodies exert potent anti-tumor activity by targeting EGF-like repeat epitope of EpCAM
by: Xiaofeng Zhou, et al.
Published: (2025-02-01) -
Targeting CD44 and EpCAM with Antibody Dye Conjugates for the Photoimmunotherapy of Prostate Cancer
by: Isis Wolf, et al.
Published: (2025-01-01) -
Landscape of cancer associated EpCAM mutations: molecular modeling, predictive insights and impact on patient survival
by: Priyanka S. Dhotare, et al.
Published: (2025-07-01) -
Biological roles and clinical applications of EpCAM in HCC
by: Peng Liu, et al.
Published: (2025-03-01)